Tigermed Announces 2026 Interim Results

Hangzhou Tigermed Consulting Co., Ltd. has announced its financial results for the first half of 2026. The company, listed on the Shenzhen (300347.SZ) and Hong Kong (3347.HK) stock exchanges, offers integrated research and development solutions for the biopharmaceutical and medical device sectors.

The announcement did not include specific financial figures, but the release of these results marks a significant point in the company's investor relations reporting cycle. Tigermed has previously outlined strategic goals for service expansion and strengthening its global market presence.

The company's services span various stages of the drug development process, aiming to expedite the market introduction of new therapies. This interim report is part of Tigermed's ongoing commitment to transparent communication with its stakeholders.

Tigermed continues its operations as a global entity in the field of drug development support services. Future financial disclosures will provide further details on the company's economic performance and outlook.